- Home
- Real World Evidence - SPAF
Professor Gregory Lip compares the approach behind conducting randomized clinical trials and real-world studies for medical intervention. He also elaborates on how real-world evidence on dabigatran therapy has provided supportive and complimentary data to RCTs and contributed to improved patient outcomes.
Professor Gregory Lip compares the approach behind conducting randomized clinical trials and real-world studies for medical intervention. He also elaborates on how real-world evidence on dabigatran therapy has provided supportive and complimentary data to RCTs and contributed to improved patient outcomes.
Results from RCTs strengthened by real-world evidences can immensely support clinical decision making. The safety and efficacy of dabigatran is studied in a broad patient population across different clinical settings.
The safety profile of dabigatran is built on evidences from RCTs and comprehensive data from real-world studies; together these provide information to the medical practitioners about its safety compared to VKAs and other NOACs.
'50 countries, 5 regions, 2200 sites': GLORIA AF – one of the largest prospective RWE study, and provides long term comparative real-world outcomes of oral anticoagulants for AF.
